Company Description

ProtGen ProTgen is developing a new class of transformative medicines to restore immune competence by unlocking the therapeutic potential of the Notch signaling pathway. Traditionally considered undruggable, ProTgen has overcome this barrier with its proprietary targeted Notch activator platform—a versatile technology capable of programming cell fate both in vivo and ex vivo. The company’s initial focus is to reactivate the thymus and rebuild a diverse, functional immune repertoire for patients with compromised or aging immune systems.